drugset / Trial / NCT06210438
SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases
NaSingle-groupOpen-labelTreatment
Summary
This is a phaseⅡ, single-arm study evaluating the efficacy and safety of SHR-A1921 Combined with Bevacizumab in Triple-negative Breast Cancer with Brain Metastases
Timeline
- Start
- 2024-02-01
- Primary completion
- 2025-06-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | SHR-A1921 | Monoclonal antibody | — | — |